b"Goodrich teamed up with Amanda Guth, Ph.D., DVM, Senior Principal Scientist at Zoetis and an associate professor who was doing research on cancers in animals. She was intrigued by his idea, and the two set out to put the technology to the test and create PhotonPharma in 2018. Goodrichs longtime friend and colleague Alan Rudolph, Ph.D. joined as CEO in 2023 after retiring from his role as CSUs Vice President of Research.PhotonPharma targeted ovarian cancer initially because it produces numerous tumor cells, and half of the patients will relapse within the first three to five years after conventional treatment. If they do relapse, the survival rate drops to 30%.investigational new drug application fromAbove: Ray Goodrich, Ph.D. found the collaboration and PhotonPharmas pre-clinical studies in micethe U.S. Food & Drug Administration.support he needed at CSU to launch PhotonPharma. and pre-clinical safety study in dogs withItsopeningupnewopportunitiesforPreviously, he led the Center tumors proved successful. Now, backedpatients to receive treatment who had veryfor Infectious Disease Research at CSU, one of Colorado's 34 by $4 million from investors, the startup islittle hope, says Goodrich. Our goal is notfederal labs. Left: Ray Goodrich, starting Phase I human clinical trials, andonly to deliver something that is safe andCo-Founder & Chief Scientific in February it received clearance for itseffective, but also affordable.Officer, PhotonPharma 2024-2025 BIOSCIENCE COLORADO 21"